Chemed (NYSE:CHE) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Chemed from a "hold" to a "buy", but the consensus remains a "Hold" (two Buy vs four Hold) with an average price target of $501.50.
• Chemed reported Q1 EPS of $5.65, beating estimates by $0.35 while revenue of $657.5M slightly missed forecasts, and the company set FY2026 guidance of 24.00–24.75 EPS versus analysts' ~22.3 EPS expectation.

Chemed (NYSE:CHE - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

Several other research analysts have also issued reports on CHE. Jefferies Financial Group lowered shares of Chemed from a "buy" rating to a "hold" rating in a research report on Thursday, January 22nd. Zacks Research raised shares of Chemed from a "strong sell" rating to a "hold" rating in a research note on Monday, April 27th. Oppenheimer decreased their price objective on shares of Chemed from $580.00 to $500.00 and set an "outperform" rating on the stock in a research note on Friday, February 27th. Weiss Ratings raised shares of Chemed from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday. Finally, Royal Bank Of Canada upped their price objective on shares of Chemed from $422.00 to $436.00 and gave the stock a "sector perform" rating in a research note on Monday. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Chemed has a consensus rating of "Hold" and an average price target of $501.50.

Chemed Stock Performance

NYSE:CHE opened at $421.65 on Friday. Chemed has a 12-month low of $365.20 and a 12-month high of $583.96. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $5.60 billion, a PE ratio of 22.98, a price-to-earnings-growth ratio of 1.59 and a beta of 0.54. The firm has a 50-day moving average price of $399.29 and a 200 day moving average price of $426.04.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The firm had revenue of $657.51 million during the quarter, compared to analyst estimates of $659.22 million. During the same quarter in the prior year, the business posted $5.63 earnings per share. The company's quarterly revenue was up 1.6% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Research analysts anticipate that Chemed will post 22.3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company's stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $403.18, for a total transaction of $806,360.00. Following the sale, the chief executive officer directly owned 93,719 shares of the company's stock, valued at approximately $37,785,626.42. This represents a 2.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.33% of the company's stock.

Hedge Funds Weigh In On Chemed

Large investors have recently modified their holdings of the stock. Monetary Solutions Ltd acquired a new position in shares of Chemed during the fourth quarter worth approximately $25,000. Los Angeles Capital Management LLC acquired a new position in shares of Chemed during the fourth quarter worth approximately $26,000. Smartleaf Asset Management LLC lifted its position in shares of Chemed by 71.4% during the third quarter. Smartleaf Asset Management LLC now owns 60 shares of the company's stock worth $27,000 after purchasing an additional 25 shares in the last quarter. BOK Financial Private Wealth Inc. acquired a new position in shares of Chemed during the fourth quarter worth approximately $27,000. Finally, First Horizon Corp acquired a new position in shares of Chemed during the third quarter worth approximately $31,000. 95.85% of the stock is currently owned by institutional investors and hedge funds.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.